Opsonic phagocytosis of Plasmodium falciparum merozoites: Mechanism in human immunity and a correlate of protection against malaria

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Osier, Faith H A ^a,b   Feng, Gaoqian ^b   Boyle, Michelle J ^b   Langer, Christine ^b   Zhou, Jingling ^b   Richards, Jack S ^b   McCallum, Fiona J ^c   Reiling, Linda ^b   Jaworowski, Anthony ^b   Anders, Robin F ^d   Marsh, Kevin ^a   Beeson, James G ^b,e  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b BURNET INSTITUTE   (Australia)

^c AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

immunity; Malaria; merozoites; monocytes; phagocytosis; Plasmodium falciparum; vaccines

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; MICROORGANISM PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; APICAL MEMBRANE ANTIGEN 1; CELL PROTEIN; ERYTHROCYTE BINDING ANTIGEN 175; MEMBRANE ANTIGEN; MSP 1 PROTEIN; MSP 2 PROTEIN; MSP 3 PROTEIN; MALARIA VACCINE; PARASITE ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; CHILD; EXPOSURE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOASSAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MEROZOITE; MONOCYTE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; REINFECTION; ANTIGEN BINDING; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; INFECTION RISK; MALARIA CONTROL; OPSONIC PHAGOCYTOSIS; PARASITE ISOLATION; PATIENT RISK; PERIPHERAL BLOOD MONONUCLEAR CELL; RISK ASSESSMENT; RISK FACTOR; TH1 CELL; VALIDATION STUDY; ANIMAL; FEMALE; IMMUNOLOGY; INFANT; MALARIA FALCIPARUM; MALE; PARASITOLOGY; PRESCHOOL CHILD;

ANIMALS; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEROZOITES; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM;

EID: 84904305506     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-108     Document Type: Article

References (55)

1. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006, 28:51-60.
2. Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol 2008, 24:578-584.
3. Cohen S, McGregor I, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
4. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991, 45:297-308.
5. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, Molina DM, Burk CR, Waisberg M, Jasinskas A, Tan X, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang X, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner PL, Pierce SK. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 2010, 107:6958-6963.
6. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008, 76:2240-2248.
7. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013, 191:795-809.
8. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 2010, 51:e50-e60.
9. Beeson JG, Fowkes FJ, Reiling L, Osier FH, Drew DR, Brown GV. Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research. Malaria Vaccine Development 2014, 3-26. London: Future Science Group, Corradin G, Engers H.
10. Duncan CJ, Hill AV, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. Hum Vaccin Immunother 2012, 8:706-714.
11. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 2008, 3:e3557.
12. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 2008, 3:e3571.
13. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 2005, 191:264-271.
14. Joos C, Marrama L, Polson HE, Corre S, Diatta AM, Diouf B, Trape JF, Tall A, Longacre S, Perraut R. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 2010, 5:e9871.
15. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, Druilhe PL. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 2007, 178:3099-3106.
16. Khusmith S, Druilhe P. Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect Immun 1983, 41:219-223.
17. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009, 77:1165-1174.
18. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182:409-418.
19. Khusmith S, Druilhe P. Specific arming of monocytes by cytophilic IgG promotes Plasmodium falciparum merozoite ingestion. Trans R Soc Trop Med Hyg 1982, 76:423-424.
20. Hill DL, Eriksson EM, Carmagnac AB, Wilson DW, Cowman AF, Hansen DS, Schofield L. Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS One 2012, 7:e51692.
21. Stubbs J, Olugbile S, Saidou B, Simpore J, Corradin G, Lanzavecchia A. Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies. Infect Immun 2011, 79:1143-1152.
22. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 2005, 191:1932-1939.
23. Mbogo CM, Mwangangi JM, Nzovu J, Gu W, Yan G, Gunter JT, Swalm C, Keating J, Regens JL, Shililu JI, Githure JI, Beier JC. Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J Trop Med Hyg 2003, 68:734-742.
24. Mbogo CN, Snow RW, Kabiru EW, Ouma JH, Githure JI, Marsh K, Beier JC. Low-level Plasmodium falciparum transmission and the incidence of severe malaria infections on the Kenyan coast. Am J Trop Med Hyg 1993, 49:245-253.
25. Agak GW, Bejon P, Fegan G, Gicheru N, Villard V, Kajava AV, Marsh K, Corradin G. Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya. Vaccine 2008, 26:1963-1971.
26. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, Bull P, Marsh K. Analysis of immunity to febrile malaria in children: an analysis that distinguishes immunity from lack of exposure. Infect Immun 2009, 77:1917-1923.
27. Mackintosh CL, Christodoulou Z, Mwangi TW, Kortok M, Pinches R, Williams TN, Marsh K, Newbold CI. Acquisition of naturally occurring antibody responses to recombinant protein domains of Plasmodium falciparum erythrocyte membrane protein 1. Malar J 2008, 7:155.
28. Mackintosh CL, Mwangi T, Kinyanjui SM, Mosobo M, Pinches R, Williams TN, Newbold CI, Marsh K. Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int J Parasitol 2008, 38:1445-1454.
29. Osier FH, Polley SD, Mwangi T, Lowe B, Conway DJ, Marsh K. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol 2007, 29:387-394.
30. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004, 23:718-728.
31. Taylor TE, Molyneux ME, Wirima JJ, Borgstein A, Goldring JD, Hommel M. Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin Exp Immunol 1992, 90:357-362.
32. Feng G, Aitken E, Yosaatmadja F, Kalilani L, Meshnick SR, Jaworowski A, Simpson JA, Rogerson SJ. Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy. J Infect Dis 2009, 200:299-306.
33. Beeson JG, Brown GV, Molyneux ME, Mhango C, Dzinjalamala F, Rogerson SJ. Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. J Infect Dis 1999, 180:464-472.
34. Boyle MJ, Wilson DW, Beeson JG. New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology. Int J Parasitol 2013, 43:1-10.
35. Boyle MJ, Wilson DW, Richards JS, Riglar DT, Tetteh KK, Conway DJ, Ralph SA, Baum J, Beeson JG. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A 2010, 107:14378-14383.
36. Ataide R, Hasang W, Wilson DW, Beeson JG, Mwapasa V, Molyneux ME, Meshnick SR, Rogerson SJ. Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria. PLoS One 2010, 5:e10807.
37. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, Petter M, Chesson JM, Langer C, Warimwe GM, Duffy MF, Rogerson SJ, Bull PC, Cowman AF, Marsh K, Beeson JG. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest 2012, 122:3227-3238.
38. Marzio R, Jirillo E, Ransijn A, Mauel J, Corradin SB. Expression and function of the early activation antigen CD69 in murine macrophages. J Leukoc Biol 1997, 62:349-355.
39. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005, 26:136-140.
40. Boeuf PS, Loizon S, Awandare GA, Tetteh JK, Addae MM, Adjei GO, Goka B, Kurtzhals JA, Puijalon O, Hviid L, Akanmori BD, Behr C. Insights into deregulated TNF and IL-10 production in malaria: implications for understanding severe malarial anaemia. Malar J 2012, 11:253.
41. Polley SD, Tetteh KK, Lloyd JM, Akpogheneta OJ, Greenwood BM, Bojang KA, Conway DJ. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007, 195:279-287.
42. Adda CG, MacRaild CA, Reiling L, Wycherley K, Boyle MJ, Kienzle V, Masendycz P, Foley M, Beeson JG, Norton RS, Anders RF. Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2. Infect Immun 2012, 80:4177-4185.
43. Reiling L, Richards JS, Fowkes FJ, Wilson DW, Chokejindachai W, Barry AE, Tham WH, Stubbs J, Langer C, Donelson J, Michon P, Tavul L, Crabb BS, Siba PM, Cowman AF, Mueller I, Beeson JG. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS One 2012, 7:e45253.
44. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
45. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989, 83:293-303.
46. Boyle MJ, Langer C, Chan JA, Hodder AN, Coppel RL, Anders RF, Beeson JG. Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum. Infect Immun 2014, 82:924-936.
47. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, Audran R, Bouzidi A, Oeuvray C, Roussilhon C. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005, 2:e344.
48. McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, Tierney E, Aked-Hurditch H, Adda C, Cross N, Richards JS, Fowkes FJ, Boyle MJ, Long C, Druilhe P, Beeson JG, Anders RF. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One 2011, 6:e24413.
49. Crabb BS, Beeson JG, Amino R, Menard R, Waters A, Winzeler EA, Wahlgren M, Fidock DA, Nwaka S. Perspectives: the missing pieces. Nature 2012, 484:S22-S23.
50. Shi YP, Udhayakumar V, Oloo AJ, Nahlen BL, Lal AA. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg 1999, 60:135-141.
51. Lund PK, Joo GB, Westvik AB, Ovstebo R, Kierulf P. Isolation of monocytes from whole blood by density gradient centrifugation and counter-current elutriation followed by cryopreservation: six years' experience. Scand J Clin Lab Invest 2000, 60:357-365.
52. Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol 2001, 98:20-28.
53. Hill DL, Eriksson EM, Li Wai Suen CS, Chiu CY, Ryg-Cornejo V, Robinson LJ, Siba PM, Mueller I, Hansen DS, Schofield L. Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One 2013, 8:e74627.
54. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
55. Muniz-Junqueira MI, dos Santos-Neto LL, Tosta CE. Influence of tumor necrosis factor-alpha on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell Immunol 2001, 208:73-79.